The importance of establishing access fluency

Stephen Daniel
Stephen Daniel
Stephen Daniel
Director in the commercial center of excellence, Campbell Alliance

Cost pressures and the increased focus on quality care and health outcomes are changing how payers approach reimbursement decisions. With more scrutiny going into prescription coverage decisions, physicians and patients are more frequently facing uncertainty about which therapeutics will or will not be covered by payers.

First and foremost, physicians are concerned about their patients having access to treatments. Is this product covered? Will it get switched at the pharmacy? Will the cost to the patient impact compliance and persistency? If the product is buy-and-bill, how will changes in reimbursement impact the physician's office financially?

As the environment becomes more complex, manufacturers have an opportunity to help physicians navigate the ever-changing health system to facilitate reimbursement and/or access of products for patients.

For a sales representative walking into a physician's office, being able to discuss the on-label clinical benefits of the product is not enough. It is important to be able to talk about how clinically appropriate patients will be able to receive the desired treatment.

To facilitate this, manufacturers have customer-facing team members at their disposal, from sales reps to reimbursement specialists, account managers, medical science liaisons (MSLs), etc.

To better serve their customers, all customer-facing team members must speak the same language and understand the reimbursement landscape. In short, they need to become fluent in the language of market access and reimbursement.

Sales reps and other customer-facing team members need to understand how any physician office functions in relation to reimbursement questions. Is the office savvy in regards to reimbursement issues? Are the office and its patients willing to take risks? Or do they accept the policies and treatment protocols or guidelines in place that may restrict access?

Access fluency means understanding the challenges that physicians face when trying to get reimbursed or when conversing with patients about coverage. If a pharmaceutical representative understands what the physician is going through, he or she can have a more informed conversation and more effectively provide guidance and support.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.